Abstract
Primary pulmonary hypertension is a rare disease in childhood associated with a poor prognosis. However, during the past 10 years, pulmonary vasodilator treatment has somewhat improved its prognosis. Long term continuous infusion of prostacyclin (epoprostenol) has been shown to improve physical capacity and to reduce mortality in primary and secondary pulmonary hypertension. It has been reported in adults that daily repetitive inhalation of iloprost, a prostacyclin analogue, seems also suitable for long term therapy of pulmonary hypertension. Repetitive inhalation of iloprost was administered to a 5 year old boy with severe primary pulmonary hypertension. He showed continuous clinical improvement without any side effects over the three years of treatment. This treatment may offer an alternative to continuous intravenous prostacyclin infusion and obviates the need for a permanent central venous catheter. Keywords: iloprost; inhalation; prostacyclin; pulmonary hypertension
Full Text
The Full Text of this article is available as a PDF (64.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barst R. J., Maislin G., Fishman A. P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999 Mar 9;99(9):1197–1208. doi: 10.1161/01.cir.99.9.1197. [DOI] [PubMed] [Google Scholar]
- Barst R. J. Role of atrial septostomy in the treatment of pulmonary vascular disease. Thorax. 2000 Feb;55(2):95–96. doi: 10.1136/thorax.55.2.95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Barst R. J., Rubin L. J., Long W. A., McGoon M. D., Rich S., Badesch D. B., Groves B. M., Tapson V. F., Bourge R. C., Brundage B. H. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296–301. doi: 10.1056/NEJM199602013340504. [DOI] [PubMed] [Google Scholar]
- Grant S. M., Goa K. L. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs. 1992 Jun;43(6):889–924. doi: 10.2165/00003495-199243060-00008. [DOI] [PubMed] [Google Scholar]
- Higenbottam T., Butt A. Y., McMahon A., Westerbeck R., Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart. 1998 Aug;80(2):151–155. doi: 10.1136/hrt.80.2.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hoeper M. M., Schwarze M., Ehlerding S., Adler-Schuermeyer A., Spiekerkoetter E., Niedermeyer J., Hamm M., Fabel H. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000 Jun 22;342(25):1866–1870. doi: 10.1056/NEJM200006223422503. [DOI] [PubMed] [Google Scholar]
- McLaughlin V. V., Genthner D. E., Panella M. M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998 Jan 29;338(5):273–277. doi: 10.1056/NEJM199801293380501. [DOI] [PubMed] [Google Scholar]
- Olschewski H., Walmrath D., Schermuly R., Ghofrani A., Grimminger F., Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 1996 May 1;124(9):820–824. doi: 10.7326/0003-4819-124-9-199605010-00006. [DOI] [PubMed] [Google Scholar]
- Rimensberger P. C., Spahr-Schopfer I., Berner M., Jaeggi E., Kalangos A., Friedli B., Beghetti M. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation. 2001 Jan 30;103(4):544–548. doi: 10.1161/01.cir.103.4.544. [DOI] [PubMed] [Google Scholar]
- Rozkovec A., Montanes P., Oakley C. M. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J. 1986 May;55(5):449–458. doi: 10.1136/hrt.55.5.449. [DOI] [PMC free article] [PubMed] [Google Scholar]